BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33049447)

  • 1. B7-H3 expression in upper tract urothelial carcinoma associates with adverse clinicopathological features and poor survival.
    Koyama Y; Morikawa T; Miyama Y; Miyakawa J; Kawai T; Kume H; Sawabe M; Ushiku T
    Pathol Res Pract; 2020 Dec; 216(12):153219. PubMed ID: 33049447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
    Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
    Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
    Tomiyama E; Fujita K; Rodriguez Pena MDC; Taheri D; Banno E; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Takao T; Yamaguchi S; Fushimi H; Yoshimura K; Uemura H; Netto GJ; Nonomura N
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Positivity Associated With Presence of Tertiary Lymphoid Structures and High-Stage Disease in Upper Tract Urothelial Carcinoma.
    Smith ME; Farahani SJ; Chao T; Palmer M; Arriola A; Lal P
    Am J Clin Pathol; 2020 Nov; 154(6):802-810. PubMed ID: 32864684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
    Reis H; Serrette R; Posada J; Lu V; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Iyer G; Funt SA; Teo MY; Rosenberg JE; Bajorin DF; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Am J Surg Pathol; 2019 Jul; 43(7):920-927. PubMed ID: 31135485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma.
    Mizuno T; Kamai T; Tsuzuki T; Nishihara D; Kijima T; Arai K; Yoshida KI
    Cancer Immunol Immunother; 2022 Mar; 71(3):565-578. PubMed ID: 34275008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma.
    Makise N; Morikawa T; Nakagawa T; Ichimura T; Kawai T; Matsushita H; Kakimi K; Kume H; Homma Y; Fukayama M
    Hum Pathol; 2016 Apr; 50():62-9. PubMed ID: 26997439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.
    Krabbe LM; Heitplatz B; Preuss S; Hutchinson RC; Woldu SL; Singla N; Boegemann M; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Rapoport LM; Glybochko PV; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Xylinas E; Margulis V
    J Urol; 2017 Dec; 198(6):1253-1262. PubMed ID: 28668287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.
    Xylinas E; Robinson BD; Kluth LA; Volkmer BG; Hautmann R; Küfer R; Zerbib M; Kwon E; Thompson RH; Boorjian SA; Shariat SF
    Eur J Surg Oncol; 2014 Jan; 40(1):121-7. PubMed ID: 24140000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count.
    Miyama Y; Morikawa T; Miyakawa J; Koyama Y; Kawai T; Kume H; Fukayama M
    Cancer Med; 2018 Sep; 7(9):4330-4338. PubMed ID: 30062756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
    Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
    Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study.
    Mathieu R; Klatte T; Margulis V; Karam JA; Rouprêt M; Seitz C; Karakiewicz PI; Fajkovic H; Wood CG; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Bensalah K; Lotan Y; Rink M; Kluth LA; Scherr DS; Robinson BD; Shariat SF
    Urol Oncol; 2015 Nov; 33(11):495.e15-22. PubMed ID: 26228160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    Cha EK; Shariat SF; Kormaksson M; Novara G; Chromecki TF; Scherr DS; Lotan Y; Raman JD; Kassouf W; Zigeuner R; Remzi M; Bensalah K; Weizer A; Kikuchi E; Bolenz C; Roscigno M; Koppie TM; Ng CK; Fritsche HM; Matsumoto K; Walton TJ; Ehdaie B; Tritschler S; Fajkovic H; Martínez-Salamanca JI; Pycha A; Langner C; Ficarra V; Patard JJ; Montorsi F; Wood CG; Karakiewicz PI; Margulis V
    Eur Urol; 2012 Apr; 61(4):818-25. PubMed ID: 22284969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
    Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI
    Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
    Jiang D; Song Q; Wang H; Huang J; Wang H; Hou J; Li X; Xu Y; Sujie A; Zeng H; Tan L; Hou Y
    Oncotarget; 2017 Jan; 8(5):8315-8329. PubMed ID: 28039448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression status of PD-L1 and B7-H3 in mesothelioma.
    Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
    Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
    Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
    Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
    Boorjian SA; Sheinin Y; Crispen PL; Farmer SA; Lohse CM; Kuntz SM; Leibovich BC; Kwon ED; Frank I
    Clin Cancer Res; 2008 Aug; 14(15):4800-8. PubMed ID: 18676751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.